ReviewAPL bioengineering2021
Surface engineering at the nanoscale: A way forward to improve coronary stent efficacy.
Review in APL bioengineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Evaluation of Graphene as a Novel Bioactive Stent Coating: Comparative Performance and Vascular Response in Porcine Coronary Arteries.Journal of functional biomaterials · 2026Article
- Recurrent subacute stent thrombosis after drug-eluting stent implantation: a case report.BMC cardiovascular disorders · 2025Article
- Biofunctional coatings and drug-coated stents for restenosis therapy.Materials today. Bio · 2024Review
- Nanotexture and crystal phase regulation for synergistic enhancement in re-endothelialization on medical pure titanium surface.Materials today. Bio · 2024Article
- Article
- Coatings for Cardiovascular Stents-An Up-to-Date Review.International journal of molecular sciences · 2024Review
- Drug-eluting stents for coronary artery disease in the perspective of bibliometric analysis.Frontiers in cardiovascular medicine · 2024Review
- Evolution of Coronary Stent Platforms: A Brief Overview of Currently Used Drug-Eluting Stents.Journal of clinical medicine · 2023Review
- Drug-Eluting Stents: Technical and Clinical Progress.Biomimetics (Basel, Switzerland) · 2023Review
- Hypersensitivity and in-stent restenosis in coronary stent materials.Frontiers in bioengineering and biotechnology · 2022Review
- Applying Principles of Regenerative Medicine to Vascular Stent Development.Frontiers in bioengineering and biotechnology · 2022Review
- Advances in Use of Nanomaterials for Musculoskeletal Regeneration.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary in-stent restenosis and late stent thrombosis are the two major inadequacies of vascular stents that limit its long-term efficacy. Although restenosis has been successfully inhibited through the use of the current clinical drug-eluting stent which releases antiproliferative drugs, problems of late-stent thrombosis remain a concern due to polymer hypersensitivity and delayed re-endothelialization. Thus, the field of coronary stenting demands devices having enhanced compatibility and effectiveness to endothelial cells. Nanotechnology allows for efficient modulation of surface roughness, chemistry, feature size, and drug/biologics loading, to attain the desired biological response. Hence, surface topographical modification at the nanoscale is a plausible strategy to improve stent performance by utilizing novel design schemes that incorporate nanofeatures via the use of nanostructures, particles, or fibers, with or without the use of drugs/biologics. The main intent of this review is to deliberate on the impact of nanotechnology approaches for stent design and development and the recent advancements in this field on vascular stent performance.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.